AZN
AstraZeneca PLC
SEC filings
Recent issuer filings from EDGAR · 25 shown
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | DATROWAY APPROVED IN EU FOR TNBC | Filing Doc | |
| 6-K | FORM 6-K | Filing Doc | |
| 6-K | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS | Filing Doc | |
| 6-K | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA | Filing Doc | |
| 6-K | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER | Filing Doc | |
| 6-K | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR | Filing Doc | |
| 6-K | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL | Filing Doc | |
| 4 | OWNERSHIP DOCUMENT | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | Filing Doc | |
| 6-K | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC | Filing Doc | |
| 6-K | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS | Filing Doc | |
| 4 | OWNERSHIP DOCUMENT | Filing Doc | |
| 6-K | TRUQAP APPROVED IN US FOR PROSTATE CANCER | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | Filing Doc | |
| 6-K | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER | Filing Doc | |
| 6-K | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED | Filing Doc | |
| 6-K | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU | Filing Doc | |
| 6-K | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS | Filing Doc | |
| 6-K | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC | Filing Doc | |
| 4 | OWNERSHIP DOCUMENT | Filing Doc | |
| 6-K | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS | Filing Doc | |
| 6-K | BAXFENDY APPROVED IN THE US FOR HYPERTENSION | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc |
No filings match this filter.
History
1 periods · newest first · EPS & Rev stacked
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q2 | 27 Jul | EPS | 2.50 | 2.63 | Beat +5.2% |
| Rev | — | $15.38B | — |
Consensus estimates via FMP · SEC filings remain the official record · not investment advice